TG Therapeutics, Inc.'s Phase 1 results of subcutaneous Briumvi are a major de-risking event for TG's most important clinical development program. SC Briumvi's bioavailability, safety, and tolerability support expectations of non-inferiority to IV Briumvi, with phase 3 topline data expected late 2026 or early 2027. IV Briumvi's sequential growth has improved, with 2026 U.S. sales guidance raised to $885–900 million and with potential for beat-and-raise trends to continue.